Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Rhea-AI Summary

Altimmune (Nasdaq: ALT) will report first quarter 2026 financial results on Wednesday, May 13, 2026 and will host a conference call at 8:30 a.m. ET the same day. The call will be webcast live on the company's Investor Relations website and a replay will be available for up to three months.

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases; management will provide a business update during the call.

News Market Reaction – ALT

+6.54%

21 alerts

+6.54% Session close to close

-3.7% Trough in 3 hr 37 min

$604.93M Market Cap

0.4x Rel. Volume

In the May 6 session, ALT gained 6.54%, reflecting a notable positive market reaction. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.5% in the session following this news. A strong positive reaction aligns with how...

Analysis

The stock moved +6.5% in the session following this news. A strong positive reaction aligns with how focused investors have been on Altimmune’s clinical and financing path, including recent offerings and a robust cash position of $274M at year-end 2025. Historically, an earlier earnings-date notice preceded a modest decline of -2.19%, so a sharp upside move would represent a departure from that pattern. Existing capital-raising capacity under the $400,000,000 shelf and prior use of prospectus supplements could remain an overhang if enthusiasm extended too far.

Key Figures

Current Price: $3.06 52-week Range: $2.56 – $7.73 Market Cap: $586,952,635 +3 more

6 metrics

Current Price $3.06 Pre-announcement trading level for ALT

52-week Range $2.56 – $7.73 ALT 52-week low and high levels

Market Cap $586,952,635 Equity value before Q1 2026 earnings release

Shelf Registration $400,000,000 Maximum aggregate offering under Form S-3/A filed Nov 13, 2025

Earnings Call Time 8:30 a.m. ET Scheduled Q1 2026 results and business update on May 13, 2026

Replay Duration Three months Webcast replay availability after the May 13, 2026 call

Previous Earnings date Reports

1 past event · Latest: Feb 26 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Earnings date notice	Neutral	-2.2%	Announcement of Q4 and full-year 2025 results call and webcast timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date announcements were followed by a modest single-day decline.

Recent Company History

Recent history shows financing and clinical build-out alongside routine communication events. In late April 2026, Altimmune completed and priced an oversubscribed offering intended to fund Phase 3 MASH work, with shares and warrants sold around $3.00. Earlier, March 2026 results highlighted $274M in cash and FDA Breakthrough Therapy Designation for pemvidutide. A prior earnings-date release on Feb 26, 2026 preceded a -2.19% move, providing the closest analogue to today’s scheduling announcement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com

Media Contact:
Real Chemistry
altimmune@realchemistry.com 

FAQ

When will Altimmune (NASDAQ: ALT) report Q1 2026 financial results and when is the earnings call?

Altimmune will report Q1 2026 results on Wednesday, May 13, 2026 and host a conference call at 8:30 a.m. ET. According to Altimmune, management will discuss financial results and provide a business update during the call.

How can investors access the Altimmune (ALT) Q1 2026 conference call and webcast?

Investors can access the live webcast via Altimmune's Investor Relations website and register for dial-in details and a PIN. According to Altimmune, registration provides dial-in numbers and a unique PIN for call participation.

Will a replay of Altimmune's (ALT) May 13, 2026 conference call be available and for how long?

A replay will be available on Altimmune's Investor Relations website shortly after the call and accessible for up to three months. According to Altimmune, the replay window is limited to that three-month period for on-demand listening.

What topics will Altimmune (NASDAQ: ALT) cover during the May 13, 2026 business update?

The business update will cover first quarter 2026 financial results and company developments related to pemvidutide for liver diseases. According to Altimmune, management intends to discuss program status and corporate financials on the call.